Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Some neurotropins, including brain-derived neurotropic factor (BDNF) or nerve growth factor-β (β-NGF), play important roles in neurodevelopment and neuroprotection. We examined the plasma levels of these 2 factors in schizophrenia patients at the time of admission and after 6 weeks of treatment with risperidone. Methods: Plasma BDNF and β-NGF levels were measured in 36 schizophrenia patients and 36 healthy controls. All the patients underwent 6 weeks of treatment with risperidone. The severity of schizophrenia and response to treatment were assessed with the positive and negative syndrome scale (PANSS). We compared plasma BDNF and β-NGF levels among much-improved (n = 13, 36.1%, ≥50% PANSS score reduction), minimal-improved (n = 15, 41.7%, ≥25% and <50% PANSS score reduction) and nonresponse patients (n = 8, 22.2%, <25% PANSS score reduction). Results: At baseline, plasma BDNF had no significant difference between schizophrenia patients and controls, but β-NGF levels were significantly lower in schizophrenia patients than controls (p = 0.037). Plasma BDNF and β-NGF in all schizophrenia patients had no significant changes between pre- and posttreatment. Baseline BDNF levels were significantly lower in nonresponse patients than others (p = 0.038). After treatment, much-improved patients had significantly higher plasma BDNF than nonresponse patients (p = 0.023). However, β-NGF levels had no significant differences between them. Conclusions: Our data suggest that higher plasma BDNF levels might be associated with better response to risperidone treatment, while plasma β-NGF levels might have no effect on the clinical response in schizophrenia patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Inhibition of Ocular Dominance Column Formation by Infusion of NT-4/5 or BDNF
Cabelli, R. J., Hohn, A., & Shatz, C. J. (1995) · Science · doi:10.1126/science.7886458 · Cited by 566
Epigenetic control of neurobehavioural plasticity: the role of neurotrophins
Branchi, I., Francia, N., & Alleva, E. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200409000-00006 · Cited by 133
Cited by
Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis
Green, M. J., Matheson, S. L., Shepherd, A., Weickert, C. S., & Carr, V. J. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.88 · Cited by 453
Domenici, E., Willé, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., Brittain, C., Rujescu, D., Giegling, I., Turck, C. W., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009166 · Cited by 347
Yamamori, H., Hashimoto, R., Ishima, T., Kishi, F., Yasuda, Y., Ohi, K., Fujimoto, M., Umeda-Yano, S., Ito, A., Hashimoto, K., et al. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.059 · Cited by 101
Kudlek Mikulic, S., Mihaljevic-Peles, A., Sagud, M., Bajs Janovic, M., Ganoci, L., Grubisin, J., Kuzman Rojnic, M., Vuksan Cusa, B., Bradaš, Z., & Božina, N. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1340518 · Cited by 25
“showed that higher plasma BDNF levels might be associated with better response to risperidone treatment, as much-improved patients (PANSS >50%) had significantly higher plasma BDNF than nonresponse patients after the treatment (19).”
BackgroundResultInfluential
Metadata
- Authors
- Lee, B.-H., & Kim, Y.-K.
- Venue
- Neuropsychobiology
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 59
- Issue
- 1
- Pages
- 51-58
- ISSN
- 0302-282X (ISSN-L)
- 1423-0224
- OpenAlex
- W1996891152
- Cited by
- 69
- References
- 4
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment. https://app.cochat.ai/papers/10.1159/000205518
- The paper
- Lee, B.-H., & Kim, Y.-K. (2009). Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment. Neuropsychobiology. https://doi.org/10.1159/000205518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.